S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
S&P 500   3,851.85
DOW   31,188.38
QQQ   323.77
Log in
NASDAQ:FLDM

Fluidigm Stock Forecast, Price & News

$5.86
-0.07 (-1.18 %)
(As of 01/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.83
Now: $5.86
$6.20
50-Day Range
$5.94
MA: $6.31
$7.15
52-Week Range
$1.17
Now: $5.86
$12.45
Volume1.42 million shs
Average Volume1.50 million shs
Market Capitalization$434.34 million
P/E RatioN/A
Dividend YieldN/A
Beta1.87
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. It sells instruments, consumables, and services to academic institutions, clinical research laboratories, and contract research organizations, as well as biopharmaceutical, biotechnology, and agricultural biotechnology companies. Fluidigm Corporation sells its products to academic institutions, life sciences, and clinical research laboratories that conduct research, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Fluidigm logo

MarketRank

Overall MarketRank

1.76 out of 5 stars

Medical Sector

162nd out of 1,928 stocks

Analytical Instruments Industry

5th out of 29 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:FLDM
CUSIP34385P10
Phone650-266-6000
Employees566

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.24 million
Book Value$2.21 per share

Profitability

Net Income$-64,790,000.00

Miscellaneous

Market Cap$434.34 million
Next Earnings Date2/10/2021 (Confirmed)
OptionableOptionable
$5.86
-0.07 (-1.18 %)
(As of 01/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for FLDM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

How has Fluidigm's stock price been impacted by Coronavirus (COVID-19)?

Fluidigm's stock was trading at $2.63 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FLDM stock has increased by 122.8% and is now trading at $5.86.
View which stocks have been most impacted by COVID-19
.

Is Fluidigm a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Fluidigm stock.
View analyst ratings for Fluidigm
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Fluidigm?

Wall Street analysts have given Fluidigm a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Fluidigm wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Fluidigm's CEO?

1,428 employees have rated Fluidigm CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 59% among Fluidigm's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release its next quarterly earnings announcement on Wednesday, February 10th 2021.
View our earnings forecast for Fluidigm
.

How can I listen to Fluidigm's earnings call?

Fluidigm will be holding an earnings conference call on Wednesday, February 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) announced its earnings results on Thursday, November, 5th. The medical research company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.12. The medical research company earned $39.86 million during the quarter, compared to the consensus estimate of $33.46 million. Fluidigm had a negative return on equity of 19.25% and a negative net margin of 37.85%.
View Fluidigm's earnings history
.

What price target have analysts set for FLDM?

3 analysts have issued 12-month price targets for Fluidigm's shares. Their forecasts range from $12.00 to $16.00. On average, they anticipate Fluidigm's stock price to reach $13.33 in the next twelve months. This suggests a possible upside of 127.5% from the stock's current price.
View analysts' price targets for Fluidigm
or view Wall Street analyst' top-rated stocks.

Are investors shorting Fluidigm?

Fluidigm saw a decline in short interest in the month of December. As of December 31st, there was short interest totaling 6,140,000 shares, a decline of 18.6% from the December 15th total of 7,540,000 shares. Based on an average trading volume of 2,150,000 shares, the days-to-cover ratio is presently 2.9 days.
View Fluidigm's Short Interest
.

Who are some of Fluidigm's key competitors?

What other stocks do shareholders of Fluidigm own?

Who are Fluidigm's key executives?

Fluidigm's management team includes the following people:
  • Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 47, Pay $688.72k)
  • Mr. Vikram Jog, Chief Financial Officer (Age 64, Pay $408.53k)
  • Mr. Bradley Allen Kreger, Sr. VP of Global Operations (Age 45, Pay $369.39k)
  • Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 46, Pay $350.47k)
  • Mr. Colin McCracken, Chief Commercial Officer (Age 47, Pay $456.65k)
  • Dr. Stephen R. Quake, Co-Founder & Chairman of Advisory Board
  • Mr. Andrew Quong, Chief Science Officer
  • Ms. Agnes Lee, VP of Investor Relations
  • Mark Spearman, Sr. Director of Corp. Communications
  • Ms. Angela Peters, Chief HR Officer

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

Who are Fluidigm's major shareholders?

Fluidigm's stock is owned by many different institutional and retail investors. Top institutional shareholders include Paradigm Capital Management Inc. NY (2.06%) and FNY Investment Advisers LLC (0.04%). Company insiders that own Fluidigm stock include Levin Easterly Partners Llc, Nicolas Barthelemy, Samuel D Colella and Stephen Christopher Linthwaite.
View institutional ownership trends for Fluidigm
.

Which major investors are buying Fluidigm stock?

FLDM stock was purchased by a variety of institutional investors in the last quarter, including Paradigm Capital Management Inc. NY, and FNY Investment Advisers LLC. Company insiders that have bought Fluidigm stock in the last two years include Nicolas Barthelemy, Samuel D Colella, and Stephen Christopher Linthwaite.
View insider buying and selling activity for Fluidigm
or or view top insider-buying stocks.

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $5.86.

How big of a company is Fluidigm?

Fluidigm has a market capitalization of $434.34 million and generates $117.24 million in revenue each year. The medical research company earns $-64,790,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. Fluidigm employs 566 workers across the globe.

What is Fluidigm's official website?

The official website for Fluidigm is www.fluidigm.com.

How can I contact Fluidigm?

Fluidigm's mailing address is 2 Tower Place Ste 2000, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.